Assessing symptom burden using the M. D. Anderson Symptom Inventory in patients with chemotherapy-induced anemia: Results of a multicenter, open-label study (SURPASS) of patients treated with darbepoetin-α at a dose of 200 μg every 2 weeks

Janice L. Gabrilove, Edith A. Perez, Dianne K. Tomita, Greg Rossi, Charles S. Cleeland

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

BACKGROUND. Patients with cancer who are receiving chemotherapy often experience chemotherapy-induced anemia (CIA), which is associated with symptoms that reduce quality of life. The M. D. Anderson Symptom Inventory (MDASI) is a brief, self-rating assessment scale that measures the severity of core symptoms and symptom interference with function. The current study used the MDASI to prospectively assess the correlation between hemoglobin and self-perceived cancer-related symptoms in a large patient population with CIA who were receiving darbepoetin-α at a dose of 200 μg every 2 weeks. METHODS. Eligible patients enrolled in this multicenter, open-label study were age ≥18 years, had a nonmyeloid malignancy, were receiving multicycle chemotherapy, and were anemic (hemoglobin ≤11 g/dL). Hemoglobin was measured every 2 weeks; the MDASI was administered weekly. For hemoglobin-based end-points, patients were stratified by baseline hemoglobin (<10 g/dL or ≥10 g/dL). RESULTS. Of 2422 enrolled patients, 2401 received ≥1 dose of darbepoetin-α. Eighty percent of patients (95% confidence limit, 78-82 patients) achieved target hemoglobin levels (≥11 g/dL) during the study. Patients with a baseline hemoglobin <10 g/dL had a greater increase in hemoglobin, took longer to achieve the target hemoglobin, and received more red blood cell transfusions than patients with a baseline hemoglobin ≥10 g/dL. The percentage of patients with moderate to severe MDASI scores (≥5 points) for fatigue, distress, loss of appetite, disturbed sleep, and interference with function was reduced during the study. Improvement in symptom burden was associated with an increase in hemoglobin concentration. CONCLUSIONS. Treatment with darbepoetin-α at a dose of 200 μg every 2 weeks is associated with improvement in symptom burden as measured by the MDASI, a simple tool that may improve symptom management for cancer patients with CIA.

Original languageEnglish (US)
Pages (from-to)1629-1640
Number of pages12
JournalCancer
Volume110
Issue number7
DOIs
StatePublished - Oct 1 2007

Fingerprint

Anemia
Hemoglobins
Drug Therapy
Equipment and Supplies
Neoplasms
Erythrocyte Transfusion
Appetite
Fatigue
Sleep
Quality of Life

Keywords

  • Anemia
  • Chemotherapy
  • Darbepoetin-α
  • Hemoglobin
  • M. D. Anderson Symptom Inventory (MDASI)
  • Quality of life
  • Symptom burden
  • Transfusions

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Assessing symptom burden using the M. D. Anderson Symptom Inventory in patients with chemotherapy-induced anemia : Results of a multicenter, open-label study (SURPASS) of patients treated with darbepoetin-α at a dose of 200 μg every 2 weeks. / Gabrilove, Janice L.; Perez, Edith A.; Tomita, Dianne K.; Rossi, Greg; Cleeland, Charles S.

In: Cancer, Vol. 110, No. 7, 01.10.2007, p. 1629-1640.

Research output: Contribution to journalArticle

@article{4c82a21c687b49dfb4a4682838f2df3a,
title = "Assessing symptom burden using the M. D. Anderson Symptom Inventory in patients with chemotherapy-induced anemia: Results of a multicenter, open-label study (SURPASS) of patients treated with darbepoetin-α at a dose of 200 μg every 2 weeks",
abstract = "BACKGROUND. Patients with cancer who are receiving chemotherapy often experience chemotherapy-induced anemia (CIA), which is associated with symptoms that reduce quality of life. The M. D. Anderson Symptom Inventory (MDASI) is a brief, self-rating assessment scale that measures the severity of core symptoms and symptom interference with function. The current study used the MDASI to prospectively assess the correlation between hemoglobin and self-perceived cancer-related symptoms in a large patient population with CIA who were receiving darbepoetin-α at a dose of 200 μg every 2 weeks. METHODS. Eligible patients enrolled in this multicenter, open-label study were age ≥18 years, had a nonmyeloid malignancy, were receiving multicycle chemotherapy, and were anemic (hemoglobin ≤11 g/dL). Hemoglobin was measured every 2 weeks; the MDASI was administered weekly. For hemoglobin-based end-points, patients were stratified by baseline hemoglobin (<10 g/dL or ≥10 g/dL). RESULTS. Of 2422 enrolled patients, 2401 received ≥1 dose of darbepoetin-α. Eighty percent of patients (95{\%} confidence limit, 78-82 patients) achieved target hemoglobin levels (≥11 g/dL) during the study. Patients with a baseline hemoglobin <10 g/dL had a greater increase in hemoglobin, took longer to achieve the target hemoglobin, and received more red blood cell transfusions than patients with a baseline hemoglobin ≥10 g/dL. The percentage of patients with moderate to severe MDASI scores (≥5 points) for fatigue, distress, loss of appetite, disturbed sleep, and interference with function was reduced during the study. Improvement in symptom burden was associated with an increase in hemoglobin concentration. CONCLUSIONS. Treatment with darbepoetin-α at a dose of 200 μg every 2 weeks is associated with improvement in symptom burden as measured by the MDASI, a simple tool that may improve symptom management for cancer patients with CIA.",
keywords = "Anemia, Chemotherapy, Darbepoetin-α, Hemoglobin, M. D. Anderson Symptom Inventory (MDASI), Quality of life, Symptom burden, Transfusions",
author = "Gabrilove, {Janice L.} and Perez, {Edith A.} and Tomita, {Dianne K.} and Greg Rossi and Cleeland, {Charles S.}",
year = "2007",
month = "10",
day = "1",
doi = "10.1002/cncr.22943",
language = "English (US)",
volume = "110",
pages = "1629--1640",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "7",

}

TY - JOUR

T1 - Assessing symptom burden using the M. D. Anderson Symptom Inventory in patients with chemotherapy-induced anemia

T2 - Results of a multicenter, open-label study (SURPASS) of patients treated with darbepoetin-α at a dose of 200 μg every 2 weeks

AU - Gabrilove, Janice L.

AU - Perez, Edith A.

AU - Tomita, Dianne K.

AU - Rossi, Greg

AU - Cleeland, Charles S.

PY - 2007/10/1

Y1 - 2007/10/1

N2 - BACKGROUND. Patients with cancer who are receiving chemotherapy often experience chemotherapy-induced anemia (CIA), which is associated with symptoms that reduce quality of life. The M. D. Anderson Symptom Inventory (MDASI) is a brief, self-rating assessment scale that measures the severity of core symptoms and symptom interference with function. The current study used the MDASI to prospectively assess the correlation between hemoglobin and self-perceived cancer-related symptoms in a large patient population with CIA who were receiving darbepoetin-α at a dose of 200 μg every 2 weeks. METHODS. Eligible patients enrolled in this multicenter, open-label study were age ≥18 years, had a nonmyeloid malignancy, were receiving multicycle chemotherapy, and were anemic (hemoglobin ≤11 g/dL). Hemoglobin was measured every 2 weeks; the MDASI was administered weekly. For hemoglobin-based end-points, patients were stratified by baseline hemoglobin (<10 g/dL or ≥10 g/dL). RESULTS. Of 2422 enrolled patients, 2401 received ≥1 dose of darbepoetin-α. Eighty percent of patients (95% confidence limit, 78-82 patients) achieved target hemoglobin levels (≥11 g/dL) during the study. Patients with a baseline hemoglobin <10 g/dL had a greater increase in hemoglobin, took longer to achieve the target hemoglobin, and received more red blood cell transfusions than patients with a baseline hemoglobin ≥10 g/dL. The percentage of patients with moderate to severe MDASI scores (≥5 points) for fatigue, distress, loss of appetite, disturbed sleep, and interference with function was reduced during the study. Improvement in symptom burden was associated with an increase in hemoglobin concentration. CONCLUSIONS. Treatment with darbepoetin-α at a dose of 200 μg every 2 weeks is associated with improvement in symptom burden as measured by the MDASI, a simple tool that may improve symptom management for cancer patients with CIA.

AB - BACKGROUND. Patients with cancer who are receiving chemotherapy often experience chemotherapy-induced anemia (CIA), which is associated with symptoms that reduce quality of life. The M. D. Anderson Symptom Inventory (MDASI) is a brief, self-rating assessment scale that measures the severity of core symptoms and symptom interference with function. The current study used the MDASI to prospectively assess the correlation between hemoglobin and self-perceived cancer-related symptoms in a large patient population with CIA who were receiving darbepoetin-α at a dose of 200 μg every 2 weeks. METHODS. Eligible patients enrolled in this multicenter, open-label study were age ≥18 years, had a nonmyeloid malignancy, were receiving multicycle chemotherapy, and were anemic (hemoglobin ≤11 g/dL). Hemoglobin was measured every 2 weeks; the MDASI was administered weekly. For hemoglobin-based end-points, patients were stratified by baseline hemoglobin (<10 g/dL or ≥10 g/dL). RESULTS. Of 2422 enrolled patients, 2401 received ≥1 dose of darbepoetin-α. Eighty percent of patients (95% confidence limit, 78-82 patients) achieved target hemoglobin levels (≥11 g/dL) during the study. Patients with a baseline hemoglobin <10 g/dL had a greater increase in hemoglobin, took longer to achieve the target hemoglobin, and received more red blood cell transfusions than patients with a baseline hemoglobin ≥10 g/dL. The percentage of patients with moderate to severe MDASI scores (≥5 points) for fatigue, distress, loss of appetite, disturbed sleep, and interference with function was reduced during the study. Improvement in symptom burden was associated with an increase in hemoglobin concentration. CONCLUSIONS. Treatment with darbepoetin-α at a dose of 200 μg every 2 weeks is associated with improvement in symptom burden as measured by the MDASI, a simple tool that may improve symptom management for cancer patients with CIA.

KW - Anemia

KW - Chemotherapy

KW - Darbepoetin-α

KW - Hemoglobin

KW - M. D. Anderson Symptom Inventory (MDASI)

KW - Quality of life

KW - Symptom burden

KW - Transfusions

UR - http://www.scopus.com/inward/record.url?scp=34648833614&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34648833614&partnerID=8YFLogxK

U2 - 10.1002/cncr.22943

DO - 10.1002/cncr.22943

M3 - Article

C2 - 17694552

AN - SCOPUS:34648833614

VL - 110

SP - 1629

EP - 1640

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 7

ER -